SCHEMBL27428474

SCHEMBL27428474

CC(C)c1cccc2c1OCC(=O)N2C(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.43
HTR1D P28221 1/20 0.43
HTR1B P28222 1/20 0.43
SLC6A4 P31645 1/20 0.43
KCNH2 Q12809 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.38
FAAH O00519 2/20 0.38
MGLL Q99685 1/20 0.38
ALOX15 P16050 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
DPP4 P27487 3/20 0.33
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
ALOX12 P18054 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTR6 P50406 1/20 0.32
ANPEP P15144 3/20 0.32
P2RX7 Q99572 1/20 0.32
CA1 P00915 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21476154 0.83 HTR1A (0.46) HTR1AHTR1DHTR1BSLC6A4KCNH2
SCHEMBL29674739 0.82 TERT (0.44) HTR1AHTR1DHTR1BSLC6A4KCNH2
SCHEMBL4971237 0.75 TSHR (0.50) ALOX15CYP2C9ALOX12ALDH1A1HTR6
SCHEMBL7350158 0.74 ALOX12 (0.47) SMN1; SMN2CYP2D6CYP2C9ALOX12ALDH1A1
SCHEMBL4101938 0.74 DRD2 (0.41) HTR1AALOX12HTR6
SCHEMBL4973366 0.73 KMO (0.49) ALOX15ALOX12ALDH1A1HTR6LMNA
SCHEMBL19910554 0.73 FAAH (0.41) SMN1; SMN2FAAHMGLLALOX15CYP2D6
SCHEMBL4970803 0.72 ALOX12 (0.47) ALOX12ALDH1A1LMNAHPGDTSHR
SCHEMBL19755649 0.72 SMN1; SMN2 (0.47) SMN1; SMN2FAAHMGLLALOX15CYP2D6
SCHEMBL4969042 0.71 HSD17B10 (0.46) ALOX12ALDH1A1CYP1A2CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217972-A1 GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. 2024-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217972-A1 GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF KRAS, VHL, HRAS HTR1A 4857/4885HTR1D 4830/4885HTR1B 4849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.